【摘要】 目的观察伊维菌素治疗蠕形螨病的效果及安全性。方法采用单盲、平行对照试验,将蠕形螨阳性者85例随机分成试验组和对照组,分别口服伊维菌素(IVMT)和新肤螨灵外用。伊维菌素为12mg(6mg/片),单次口服;新肤螨灵外用,每天早、晚各1次,连续6周。于第3周、第6周用透明胶纸法对其面部双侧鼻唇沟皮肤进行检查。结果在服药第3周末,伊维菌素对蠕形螨病的治愈率为74.42%(32/43),同期与对照组有显著性差异(P<0.05);在服药第6周末,伊维菌素对蠕形螨病的治愈率为100%(43/43),同期与对照组无显著性差异(P>0.05)。试验组未发生不良反应。结论伊维菌素治疗蠕形螨病安全有效。更多还原

【Abstract】 Objective To evaluate the curative effect and safety of ivermectin treatment on demodicidosis. Methods A single blinded and controlled study of human demodicidosis treated with ivermectin was conducted. 85 patients with demodicidosis were randomly divided into trial and control groups. A single dose of ivermectin, 12mg, was orally administered to the trial group.The control group was treated with “new fumanling”cream twice a day in the early morning and evening respectively for six weeks consecutively.At week 3 and week 6, samples were obtained and investigated by the clear tap method.Results After 3 week′s treatment, the curative rate of the trial group with demodicidosis was 74.42%(32/42), and showed a significant difference to the control group (P< 0 05). After 6 weeks treatment, the curative rate of the trial group with demodicidosis was 100%(43/43), but showed no significant difference to the control group (P >0 05). No side effect of the ivermectin treatment in the trial group was observed.Conclusion Ivermectin is highly effective to treat demodicidosis and has no prominent adverse effect.更多还原